Palmitoyl tripeptide-8 s a bioactive peptide with anti-allergen effect and has been reported used as a cosmetic ingredient.

μ-Conotoxin-CnIIIC is a 22-residue conopeptide that can be isolated from Conus consors. μ-Conotoxin-CnIIIC is a potent and persistent blocker of NaV1.4 channel. μ-Conotoxin-CnIIIC has analgesic, anaesthetic and myorelaxant properties.

Lipid C14-A1 is an ionizable lipid. C14-A1-LPN is a potent and safe LNP platform to deliver Foxp3 mRNA to CD4+ T cells to engineer immunosuppressive FP3T cells.

TB500 is a synthetic version of an active region of thymosin β4. TB500 is claimed to promote endothelial cell differentiation, angiogenesis in dermal tissues, keratinocyte migration, collagen deposition and decrease inflammation.

NVS-STG2 is a small molecule STING agonist with AC50 of 5.2 μM. NVS-STG2 induces the high-order oligomerization of human STING by binding to a pocket between the transmembrane domains of the neighboring STING dimers and elicit potent STING-mediated immune responses in cells and antitumor activities in animal models.

PROTAC BRAF-V600E degrader-1 is a potent PROTAC BRAF-V600E degrader with Kd value of 2.4 nM and 2 nM for BRAF and BRAF-V600E, respectively. PROTAC BRAF-V600E degrader-1 degrades BRAF-V600E via the ubiquitin-proteasome system (UPS). PROTAC BRAF-V600E degrader-1 can inhibit melanoma cell growth.

FASN-IN-5 (example 11), a FASN inhibitor, can be used for the research of TH17- or CSF1 -mediated disease or disorder such as cancer, immunological disorders, and obesity.

PAD-IN-2 is a potent pad4 inhibitor (IC50: <1 μM). PAD-IN-2 can be used in the research of auto-immune diseases and cancers, such as rheumatoid arthritis, vasculitis, systemic lupus erythematosis, cutaneous lupus erythematosis, ulcerative colitis, cystic fibrosis, asthma, multiple sclerosis and psoriasis.

Fenretinide Glucuronide Monosodium Salt, is the metabolite of Fenretinide (F250000), which is a synthetic retinoid deriverative, substances related to vitamin A. They are also shown to be used for the treatment of cancer, as well as in the treatment of cystic fibrosis, rheumatoid arthritis, acne, and psoriasis.

Lumigen APS-5 is a substrate of alkaline phosphatase (ALP). Lumigen APS-5 can be used to assess the activity of alkaline phosphatase (ALP).

ABX-002 is a novel CNS-penetrant TR-B agonist prodrug with potential for treatment of demyelinating disorders as well as other neuroinflammatory and/or neurodegenerative diseases.

GalNAc-Lipid GL6 is a multi-valent N-acetylgalactosamine (GalNAc) targeting ligand. GalNAc-LNP is capable of delivering a CRISPR base editing therapeutic via LDLR-independent pathways.

BI-2493 is a structural analogue of BI-2865 and a highly selective pan-KRAS inhibitor. BI-2493 can attenuate tumor growth. BI-2493 can be used for cancer iseases research.

Lipid C12-A1 is an ionizable lipid. C12-A1-LPN is a potent and safe LNP platform to deliver Foxp3 mRNA to CD4+ T cells to engineer immunosuppressive FP3T cells. C12-A1 has a slightly lower average cell viability than C14-A1.

Lipid 2-10 is an ionizable lipid (pKa=6.16) that can be used to prepare lipid nanoparticles (LNP) with bilayer structure.

RCS-03-104-4 is a cysteine-reactive JQ1 analogue, which potently induces BRD4 degradation with DC50 and Dmax of 79 nM and 71%, respectively. RCS-03-104-4 causes BRD4 degradation by inducing its proximity with the ubiquitin ligase activity of DCAF11.

RCB-4-8 is an ionizable cationic lipid that has been used in the formation of lipid nanoparticles (LNPs) for the delivery of mRNA.1 RCB-4-8-containing LNPs improve lung transfection efficiency by approximately 100-fold over MC3-containing LNPs in mice.

IR-19-Py(A20-0l) is an ionizable, degradable lipid for nebulized mRNA delivery.